Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Most Cited Paper
in Tuberculosis Research and Epidemiology
18 Months Post-Publication
Class of 2026
“Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
bedaquiline · pretomanid · moxifloxacin · pyrazinamide · Drug-susceptible tuberculosis · Drug-resistant tuberculosis · pulmonary tuberculosis · phase 2c trial · four-drug regimen · BPaMZ regimen · tuberculosis treatment shortening · Rifampicin-resistant tuberculosis · Multidrug-resistant tuberculosis · partially randomised design · treatment efficacy · safety profile · culture conversion · novel TB regimen
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Tuberculosis Research and Epidemiology Papers, Class of 2026. https://pri.pepkio.com/top-papers/tuberculosis-research-and-epidemiology/2026. Accessed 2026-07-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459